Needham analyst Gil Blum reiterated a Buy rating on Rocket Pharmaceuticals (NASDAQ:RCKT) on Thursday, setting a price target of $75, which is approximately 116.20% above the present share price of $34.69.
Blum expects Rocket Pharmaceuticals to post earnings per share (EPS) of -$0.55 for the fourth quarter of 2021.
The current consensus among 9 TipRanks analysts is for a Strong Buy rating of shares in Rocket Pharmaceuticals, with an average price target of $71.71.
The analysts price targets range from a high of $100 to a low of $56.
In its latest earnings report, released on 06/30/2021, the company reported a quarterly revenue of $0 and a net profit of -$34.05 million. The company's market cap is $2.24 billion.
According to TipRanks.com, Needham analyst Gil Blum is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -7.7% and a 40.00% success rate.
Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of first-in-class gene therapy treatment options for rare and devastating pediatric diseases. Its multi-platform development approach applies the lentiviral vector (LVV) and adeno-associated viral vector (AAV) gene therapy platforms. The firm's clinical program is a LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer. The company was founded in 1999 and is headquartered in New York, NY.